rs35829419 — NLRP3 Q705K

NLRP3 Q705K — A Hair-Trigger Inflammasome

The NLRP3 gene encodes the central sensing component of the NLRP3 inflammasome¹¹ NLRP3 inflammasome
A multiprotein innate immune complex that acts as an intracellular danger sensor, assembling in response to pathogens, crystals, fatty acids, and other signals — the innate immune platform responsible for producing IL-1beta and IL-18²² IL-1beta and IL-18
Two cytokines that drive fever, neutrophil recruitment, and systemic inflammatory cascades, two of the most potent pro-inflammatory cytokines in the body. Q705K (rs35829419) is a common missense variant that substitutes glutamine for lysine at position 703 of the protein (also referred to in older literature as position 705 due to differing isoform numbering). Unlike rare NLRP3 mutations that cause the severe cryopyrin-associated periodic syndromes (CAPS)³³ cryopyrin-associated periodic syndromes (CAPS)
Rare autoinflammatory disorders including Muckle-Wells syndrome and familial cold autoinflammatory syndrome, Q705K is a common polymorphism in European populations (about 4% carry the A allele) that subtly but measurably lowers the threshold for inflammasome activation.

The Mechanism

The Q705K substitution introduces a charged lysine residue into the NLRP3 protein's central domain, altering the conformational dynamics of the complex. Functional studies using THP-1 monocytic cells transduced with Q705K showed a five-fold increase in IL-1beta production at baseline compared to wild-type cells, without any external stimulation⁴⁴ Functional studies using THP-1 monocytic cells transduced with Q705K showed a five-fold increase in IL-1beta production at baseline compared to wild-type cells, without any external stimulation
This spontaneous activation distinguishes Q705K from normal NLRP3 behavior. Upon exposure to alum (a vaccine adjuvant and NLRP3 activator), Q705K cells produced an additional two-fold more IL-1beta than wild-type cells. The excess cytokine production operates through an autocrine feedback loop⁵⁵ autocrine feedback loop
Secreted IL-1beta binds IL-1 receptors on the same cell, amplifying downstream signaling and further driving inflammasome activation via the IL-1 receptor. Blocking either caspase-1 (the inflammasome effector enzyme) or the IL-1 receptor substantially reduces the excess production, confirming the inflammasome as the source.

The NLRP3 inflammasome is activated by a diverse array of danger signals: monosodium urate (MSU) crystals⁶⁶ monosodium urate (MSU) crystals
The deposited form of uric acid in gout in gout, intracellular lipid crystals from high saturated fat intake, cholesterol crystals in atherosclerotic plaques⁷⁷ cholesterol crystals in atherosclerotic plaques
NLRP3 activation in macrophages within arterial walls contributes to plaque instability, and bacterial toxins in the gut. With a gain-of-function Q705K variant, all of these triggers produce an amplified response.

The Evidence

A meta-analysis of 13 case-control studies totalling 7,719 patients found that the rs35829419 A allele was significantly associated with increased susceptibility across multiple inflammatory diseases⁸⁸ significantly associated with increased susceptibility across multiple inflammatory diseases
Including leprosy, colorectal cancer, HIV-1 infection, rheumatoid arthritis, abdominal aortic aneurysms, inflammatory bowel disease, ulcerative colitis, and atopic dermatitis.

For gout, the pathway is direct: uric acid crystals are among the most potent NLRP3 activators known, and the gain-of-function Q705K variant lowers the threshold for crystal-induced IL-1beta production. NLRP3 polymorphisms have been identified as contributors to gout susceptibility across multiple populations⁹⁹ NLRP3 polymorphisms have been identified as contributors to gout susceptibility across multiple populations, and the Q705K gain-of-function variant amplifies MSU-crystal-induced IL-1beta production through the same pathway, though its individual contribution to gout risk is most clearly manifest through pathway biology rather than isolated genetic association.

For inflammatory bowel disease, a landmark Swedish cohort study demonstrated that men carrying both the NLRP3 Q705K allele and the CARD8 C10X allele (rs2043211) had OR 3.40 (95% CI 1.32-8.76, p=0.011) for Crohn's disease¹⁰¹⁰ OR 3.40 (95% CI 1.32-8.76, p=0.011) for Crohn's disease
This gene-gene interaction between NLRP3 and its negative regulator CARD8 dramatically amplifies risk when both are compromised compared to those carrying neither variant. This is a gene-gene interaction of substantial clinical magnitude.

For metabolic inflammation and cardiovascular risk, a Slovenian study of 181 type 2 diabetes patients found that A allele carriers had OR 3.93 (95% CI 1.54-10.0, p=0.004) for macrovascular complications¹¹¹¹ A allele carriers had OR 3.93 (95% CI 1.54-10.0, p=0.004) for macrovascular complications
Including peripheral arterial occlusive disease, myocardial infarction, and ischemic cerebrovascular disease, even after adjusting for diabetes duration and cholesterol. The association was strongest in men.

Notably, a meta-analysis examining rs35829419 specifically in autoimmune diseases found a protective effect against rheumatoid arthritis (OR 0.74, 95% CI 0.57-0.96)¹²¹² protective effect against rheumatoid arthritis (OR 0.74, 95% CI 0.57-0.96)
The A allele may reduce susceptibility to RA through complex immune regulatory mechanisms, illustrating that the same gain-of-function variant can have disease-context-specific effects — enhancing innate immune responses that damage joints in gout while potentially reducing adaptive autoimmune processes in RA.

Practical Actions

The NLRP3 inflammasome is a well-validated druggable target. The most relevant dietary interventions work through two complementary mechanisms: increasing endogenous inhibitors of NLRP3 activation, and reducing the triggers that activate it.

EPA and DHA (omega-3 fatty acids) directly suppress NLRP3 inflammasome assembly¹³¹³ EPA and DHA (omega-3 fatty acids) directly suppress NLRP3 inflammasome assembly
Acting via GPR120 and GPR40 receptors and their downstream scaffold protein beta-arrestin-2, abolishing caspase-1 activation and IL-1beta secretion in macrophages. In animal models, omega-3 supplementation prevented NLRP3-driven metabolic inflammation in high-fat diet models. For Q705K carriers, a consistent, clinically meaningful EPA/DHA intake represents the most evidence-backed dietary strategy.

Sulforaphane, the isothiocyanate produced from glucoraphanin in broccoli sprouts¹⁴¹⁴ Sulforaphane, the isothiocyanate produced from glucoraphanin in broccoli sprouts
Broccoli sprouts contain 10-100x more glucoraphanin than mature broccoli, inhibits NLRP3 inflammasome activation by reducing reactive oxygen species and suppressing IL-1beta and IL-18 secretion.

Avoidance matters equally: dietary triggers that activate NLRP3 include fructose and alcohol (which raise serum uric acid, a potent NLRP3 activator and the pathogenic agent in gout) and high saturated fat intake, particularly palmitate¹⁵¹⁵ high saturated fat intake, particularly palmitate
Palmitate activates NLRP3 in macrophages through mitochondrial reactive oxygen species and the AMPK-autophagy signaling cascade.

Interactions

The most clinically significant interaction is with rs2043211 (CARD8 C10X). CARD8 is an endogenous negative regulator of NLRP3 — it normally dampens inflammasome activity. The C10X loss-of-function variant eliminates CARD8 function. When NLRP3 is gain-of-function (Q705K) AND its brake is absent (CARD8 C10X), the combinatorial effect in men is a 3.40-fold increase in Crohn's disease risk — far larger than either variant alone. This is a compound interaction that warrants a dedicated compound action for users carrying both genotypes.

rs2066844 (NOD2 R702W) and other NOD2 loss-of-function variants reduce bacterial sensing in the gut, placing additional pressure on NLRP3-driven innate immunity as a compensatory pathway. Carriers of both NLRP3 Q705K and a NOD2 risk variant may have dysregulated intestinal innate immunity from two directions. The compound recommendation would be heightened vigilance for IBD symptoms and close dietary management of NLRP3 triggers.

The rs10754558 NLRP3 3'UTR variant affects NLRP3 expression level via microRNA regulation and may act additively with Q705K — higher expression of an already gain-of-function protein further amplifies IL-1beta output.